The Rivkin Center for Ovarian Cancer & The American Association for Cancer Research Present the

12th Biennial Ovarian Cancer Research Symposium

September 13th-15th, 2018

UNIVERSITY OF WASHINGTON | SEATTLE, WA

12th Biennial Ovarian Cancer Research Symposium Information

The 12th Biennial Ovarian Cancer Research Symposium is presented by the Rivkin Center for Ovarian Cancer and the American Association for Cancer Research. The goal of the Symposium is to bring together clinicians and researchers from across many disciplines and institutions worldwide in order to encourage collaborations toward advancing the field of ovarian cancer research. The conference seeks to enhance the understanding and knowledge of ovarian cancer, especially among junior investigators, discuss the most recent innovations in the field of ovarian cancer research, and address pressing concerns of the leaders in the clinical and research community.

Call for Abstracts

We are now soliciting research and clinical abstracts for the following focus areas for this year’s symposium:

  • Detection and Prevention
  • Genomics and Molecular Mechanisms
  • Tumor Microenvironment & Immunology
  • Novel Therapeutics: Response & Resistance

Abstract Instructions: Abstracts should include the purpose of your study, a brief explanation of the data, and your conclusions (limit 500 words). The deadline for abstract submission is 5pm PST on July 10, 2018.

SUBMIT ABSTRACT

Registration will be open April 2, 2018.

Scholar-in-Training Awards

A limited number of Scholar-in-Training Awards are available to help offset costs for trainees to attend the symposium. Applicants must be Associate Members of the AACR in good standing, present an abstract at the Ovarian Cancer Research Symposium and not have received a Scholar-in-Training Award for a conference (excluding the AACR Annual Meeting) in the 12 months prior to the start of the symposium (September 13, 2018). An abstract for the symposium must be submitted before applying for the award. The deadline for submission is July 10, 2018, 11:59 pm EST. Full eligibility and application instructions are available here.

Continuing Medical Education Activity – AMA PRA Category 1 CreditsTM available. Visit www.rivkin.org or call 206-215-6200 for the latest information.

Important Dates


April 2, 2018

Abstract Submissions Open



April 2, 2018

Online Registration Opens



July 10, 2018

Abstract Submissions Close



August 31, 2018

Online Registration Closes (Online registration limited to availability)

Day 1: September 13, 2018

3:00 PM

Registration and Poster Set-up

4:00 PM – 4:15 PM

Welcome

4:15 PM – 5:30 PM

EDUCATION SESSION: CURRENT CHALLENGES IN OVARIAN CANCER

Biology of Ovarian Cancer
Douglas Levine, MD (NYU Langone)

Tumor Microenvironment and Immunology of Ovarian Cancer
Brad Nelson, PhD (British Columbia Cancer Agency)

Clinical Management of Ovarian Cancer
Elizabeth Swisher, MD (University of Washington)

5:30 PM – 6:30 PM

KEYNOTE ADDRESS

Mary-Claire King, PhD (University of Washington)

6:30 PM – 8:30 PM

Welcome Reception and Poster Session I

Day 2: September 14, 2018

7:30 AM – 8:30 AM

Breakfast and Registration

8:30 AM – 12:00 PM

SESSION I: DETECTION AND PREVENTION

Chair: Elizabeth Swisher, MD (University of Washington)
Invited: Ranjit Manchanda, MD/PhD (Barts Cancer Institute)
Invited: Rosana Risques, PhD (University of Washington)

12:05 PM – 1:30 PM

Lunch

12:30 PM – 1:30 PM

Meet the Experts Roundtable

1:30 PM – 5:30 PM

SESSION II: GENOMICS AND MOLECULAR MECHANISMS

Chair: Pamela Ohashi, PhD (Princess Margaret Cancer Centre)
Invited Speaker: Kathleen Cho, MD (University of Michigan)
Invited Speaker: Alan D’Andrea, MD (Dana Farber Cancer Institute)

5:15 PM – 6:30 PM

PANEL: THE ROLE OF ADVOCATES IN OVARIAN CANCER RESEARCH

Nita Maihle, PhD (Augusta University)
Marcie Paul
Jaime Crase

4th Panelist TBD

6:30 PM – 8:30 PM

Reception and Poster Session II

Day 3: September 15, 2018

7:30 AM – 8:30 AM

Breakfast and Registration

8:30 AM – 12:00 PM

SESSION III: TUMOR MICROENVIRONMENT AND IMMUNOLOGY

Chair & Invited Speaker: Frances Balkwill, PhD (Barts Cancer Institute)
Invited Speaker: Ernst Lengyel, MD/PhD (University of Chicago)

12:05 PM – 1:30 PM

Lunch

1:30 PM – 5:30 PM

SESSION IV: NOVEL THERAPEUTICS: RESPONSE AND RESISTANCE

Chair: Nora Disis, MD (University of Washington)
Invited Speaker: Ursula Matulonis, MD (Dana Farber Cancer Institute)
Invited Speaker: Jung-Min Lee, MD (National Cancer Institute)

5:30 PM

Closing Remarks & Departure

Call for Abstracts

The planning committee is now soliciting research and clinical abstracts. Submission Deadline: Monday, July 10, 2018, Pacific Time

SUBMIT ABSTRACT

Abstract should include the purpose of your study, a brief explanation of the data, and your conclusions (limit 500 words). Abstracts may be submitted for the following sessions:

  1. Detection and Prevention
  2. Genomics and Molecular Mechanisms
  3. Tumor Microenvironment and Immunology
  4. Novel Therapeutics: Response and Resistance
  5. Poster Session


The focus of the study may pertain to one of the following areas relevant to ovarian cancer research:


Animal Models
Basic Science
Bioinformatics
Cell Biology
Chemoresistance
Clinical Research
Epidemiology
Diagnostics
DNA Damage Response
DNA Repair
Early Detection
Epigenetics
Etiology
Genetics

Genomics
Immunology
Immunotherapy
Metabolomics
Novel Therapy
Pathophysiology
Preclinical Studies
Prevention
Proteomics
Public Health
Stem Cells
Survivorship
Treatment
Tumor Microenvironment

Continuing Medical Education Activity – AMA PRA Category 1 CreditsTM available.

Continuing Medical Education (CME)

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The American Association for Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer. The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) activities for physicians.

CREDIT DESIGNATION STATEMENT

AACR has designated this live activity for a maximum of 18.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

CLAIMING (CME) CREDIT

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Monday, October 29, 2018. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the 12th Biennial Ovarian Cancer Research Symposium website or via email. Your CME certificate will be sent to you via email after the completion of the activity.

STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE, AND LEARNING OBJECTIVES

Approximately 22,000 women in the United States are diagnosed with ovarian cancer every year. The overall 5-year survival rate is only 46% for ovarian cancer, and the rate is markedly lower for advanced stage cancers. Sadly, the survival rates have only improved slightly over 40 years. While ovarian cancer is the most deadly gynecologic cancer, it is underrepresented in both research funding and research participants. Additionally, complicating the difficulty in diagnosing the disease beyond its physical complexities is that ovarian cancer is a rare disease and many providers will have limited access to information on the signs, symptoms, and latest techniques to diagnose the disease.

In this course, we are addressing major needs in ovarian cancer care and research by educating health care providers and researchers in the latest research on improving treatment, early detection, and prevention, as well as promoting a better understanding of the many diseases under the umbrella of ovarian cancer.

The Planning Committee has designed this event to benefit the following audiences: basic scientists, epidemiologists, clinical scientists, and clinicians as well as geneticists, public health researchers, nurses, and advocates for ovarian cancer research. This conference encourages the collaboration between professionals with a wide variety of expertise including: gynecologic oncology, medical oncology, pathology, genetics, molecular biology, cell biology, public health, behavioral epidemiology, translational research, patient care, and patient advocacy.

After participating in this CME activity, physicians should be able to:

  • Define cancer control strategies to detect ovarian cancer at the earliest stages and to prevent the disease
  • Articulate the molecular mechanisms and genomic drivers of ovarian cancer
  • Explain the elements of tumor microenvironment and immunology as they contribute to ovarian cancer growth and as possible targets for treatment
  • Identify targeted therapies against ovarian cancer and assess the response of new therapies and lack of response in cases of recurrence and therapy resistance.

DISCLOSURE STATEMENT

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

ACKNOWLEDGMENT OF FINANCIAL OR OTHER SUPPORT

This activity is supported by Professional Educational Grants which will be disclosed at the activity.

QUESTIONS ABOUT CME?

Please contact the Office of CME at (215) 440-9300 or cme@aacr.org.

12th Biennial Ovarian Cancer Research Symposium Planning Committee

The purpose of the Symposium Planning Committee is to develop the scope and goals of the 12th Biennial Ovarian Cancer Research Symposium scheduled for September 13-15th, 2018 in Seattle. The members’ collective expertise will inform the selection of invited speakers, the review of submitted abstracts, and the identification of target audience. The Symposium seeks to enhance the understanding and knowledge of ovarian cancer, especially among junior and young investigators, discuss the most recent innovations in the field of ovarian cancer research, and address the pressing concerns among the leaders of the clinical and research community.

Planning Committee Members:

Frances Balkwill, PhD
(Co-Chair)

Barts Cancer Institute

Mary L. (Nora) Disis, MD
(Co-Chair)

University of Washington

Elizabeth Swisher, MD
(Co-Chair)

University of Washington

Pamela Ohashi, PhD
(Co-Chair)

Princess Margaret Cancer Center

Amy Baran, PhD

American Association for Cancer Research

Kiran Dhillon, PhD

Rivkin Center for Ovarian Cancer

Saul Rivkin, MD

Rivkin Center for Ovarian Cancer

Sponsorships

The Rivkin Center gratefully acknowledges our sponsors for this year’s 12th Biennial Ovarian Cancer Research Symposium. Without their vital underwriting and dedication, this event would not be possible. Thank you!

For more information about sponsoring this year’s event, please review the sponsorship packet or contact Julie Anderson, Development Manager, at (206) 215-6044.

Accommodations and Travel

The 12th Biennial Ovarian Cancer Research Symposium will be held at the University of Washington in Seattle, Washington. Symposium talks and coffee breaks will be held in Kane Hall. Registration, breakfast, lunch, receptions and poster sessions will be held in the Husky Union Building. View Map

Lodging

Marriott Residence Inn Seattle University District

Address: 4501 12th Avenue NE, Seattle, WA, 98105

Hotel to meeting venue: 7 blocks to the University of Washington campus, 0.5 mile walk (12 minutes), or Metro route 44, 49, 70 ($2.75)

Rate: $244/night

 

BOOKING INFORMATION

  • Reserve onlineBOOK MARRIOTT ONLINE
  • Reserve by phone: Call the hotel at (800) 331-3131 or (206) 322-8887 and mention Rivkin Center to receive discounted rate.

Guestroom Dates: 9/12/2018 – 9/16/2018

Discounted rate expires on 8/1/18, or when block sells out, whichever is first.

Silver Cloud Inn – Seattle Lake Union

Address: 1150 Fairview Ave N, Seattle, WA 98109, USA

Hotel to meeting venue: 2.3 mile walk, or Metro route 70 ($2.75). Complimentary University of Washington/Fred Hutch South Lake Union Shuttle between 6:45am and 6:45pm. Use the Condon Stop to get to and from the University of Washington. For maps and shuttle schedules, visit Fred Hutch Shuttle information.

Rate: $229/night King or Two Queen Bed Guestroom or $249 Lakeview King or Two Queen Bed Guestroom

 

BOOKING INFORMATION

  • Reserve onlineBOOK SILVER CLOUD ONLINE
  • Reserve by phone: Call the hotel at (206) 447-9500 and mention the “12th Biennial Ovarian Cancer Research Symposium” or “BOCRS” group to receive discounted rate.

Guestroom Dates: 9/12/2018 – 9/16/2018

Discounted rate expires on 8/1/18, or when block sells out, whichever is first.

Air Travel

All major airlines provide service into the Seattle-Tacoma International Airport (SEA), located approximately 25 minutes from the University of Washington.

Ground Transportation

Taxi Service: Taxi fare is approximately $60 from Seattle-Tacoma International Airport to hotels and meeting venue.

About Seattle

September in Seattle is generally pleasant with mild temperatures averaging a perfect 65-70 degrees Fahrenheit or 18-21 degrees Celsius. Nestled in the Puget Sound, Seattle offers a wide variety of activities for everyone. Enjoy world-renowned museums, historic Pike Place Market, Western Washington wineries, or explore the outdoors by hiking, biking, boating, or any number of adventuresome ways. Tourism information can be found at experiencewa.com.

Registration

Registration will open on April 2. If you are speaking in a scientific session, you will automatically be registered for the Symposium free of charge. Please do not register yourself online.

Registration includes entry into scientific sessions from September 13th – 15th and light breakfast, boxed lunch, coffee breaks, and evening receptions on September 13th and 14th. Advanced registration rates are available until August 13th after which regular registration rates will apply. Online registration closes on August 31st, 2018. Onsite registration at regular registration rates may be available on a first come first served basis.

Registration Rates

Advance Registration Until August 13th Regular Registration After August 13th
Physician $400 $450
Researcher $400 $450
Allied Health $175 $215
Postdoctoral or Clinical Fellow $175 $215
Research Technician $175 $215
Pre-doctoral student (Graduate/Medical/Nursing) $75 $110
Patient/Survivor $0 $0

Continuing Medical Education Activity – AMA PRA Category 1 CreditsTM available.

Visit www.rivkin.org or call 206-215-6200 for the latest information.
For questions, please contact the Rivkin Center office at 206-215-6200, or info@marsharivkin.org.

The 12th Biennial Ovarian Cancer Research Symposium is a CME Activity jointly provided by the American Association for Cancer Research and the Rivkin Center for Ovarian Cancer.